← Back to catalogue

NoFact VIII Deficient Plasma

FDA 510(k)FDA UDIEUDAMED

Class II (US FDA 510(k))

510(k) K102851Ref 68-201

by R2 Diagnostics, Inc.

Identity

Trade Name
NoFact VIII EUDAMEDFDA UDI
Generic Name
Coagulation factor VIII IVD, kit, clotting FDA UDI
Device Name
NoFact VIII EUDAMED
Factor VIII immunodepleted 10 x 1 ml FDA UDI
Model / Reference
68-201 EUDAMEDFDA UDI
Description
Factor VIII immunodepleted 10 x 1 ml FDA UDI

Identifiers

Catalog Number
68-201 FDA UDI
Primary DI / UDI-DI
10859394006153 EUDAMEDFDA UDI
Basic UDI-DI
B-10859394006153 EUDAMED
510(k) Number
K102851 FDA 510(k)FDA UDI
FDA Product Code
GJT FDA 510(k)FDA UDI
EMDN Code
W0103020207 COAGULATION FACTOR VIII EUDAMED
GMDN Term
Coagulation factor VIII IVD, kit, clotting FDA UDI

Classification

Device Class
Class IVD General EUDAMED
Class II FDA 510(k)FDA UDI
Legislation / Framework
21 CFR Part 864.7290 FDA 510(k)
Regulation Number
864.7290 FDA 510(k)FDA UDI
Market of Registration
Italy EUDAMED
Advisory Committee
Hematology FDA 510(k)
FDA Decision
SESE Substantially Equivalent FDA 510(k)
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

EUDAMEDFDA UDI

Single Use

Yes

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Human Tissues

Yes

EUDAMED

Animal Tissues

No

EUDAMED

Microbial Substances

No

EUDAMED

Reagent

Yes

EUDAMED

Self Testing

No

EUDAMED

Near-Patient Testing

No

EUDAMED

Professional Testing

Yes

EUDAMED

Companion Diagnostics

No

EUDAMED

Surgical Instrument

No

EUDAMED

Prescription Use

No

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

NoFact VIII Deficient Plasma is a human plasma substrate immunodepleted of Factor VIII, classified as a Plasma, Coagulation Factor Deficient device under the FDA nomenclature. It is designed for the quantitative determination of Factor VIII activity in citrated patient plasma, utilising an activated partial thromboplastin time assay to measure clotting factor levels in suspected FVIII deficiency cases.

This device is supplied as a single-use, in vitro diagnostic reagent intended for laboratory use. It is authorised under FDA 510(k) clearance and IVDD compliance, with a product code of GJT and device class II classification. Sterility and storage conditions are not specified in the provided data, but it is intended for use in hematology settings where precise coagulation factor measurement is required.

Frequently asked questions

What is the NOFact VIII Deficient Plasma used for in a clinical setting?

The NOFact VIII Deficient Plasma is specifically designed for the quantitative measurement of Factor VIII activity in citrated patient plasma. It uses an activated partial thromboplastin time (APTT) assay to help diagnose and monitor suspected Factor VIII deficiencies, which is critical in hematology for assessing bleeding disorders like hemophilia.

Is the NOFact VIII Deficient Plasma intended for single-use or repeated use?

The NOFact VIII Deficient Plasma is explicitly labeled as a single-use in vitro diagnostic reagent. This means each vial is intended for one test procedure only, ensuring accuracy and preventing cross-contamination in laboratory settings.

What regulatory pathways does the NOFact VIII Deficient Plasma follow?

The NOFact VIII Deficient Plasma is authorized under both FDA 510(k) clearance and IVDD compliance, confirming its adherence to stringent regulatory standards for in vitro diagnostics. It falls under product code GJT and is classified as a Class II device, indicating moderate regulatory oversight.

What types of hematology laboratories would benefit most from using the NOFact VIII Deficient Plasma?

This reagent is ideal for specialized hematology laboratories focused on coagulation studies, particularly those diagnosing or managing Factor VIII deficiencies. Its use in APTT assays makes it valuable in clinical settings where precise measurement of clotting factors is essential, such as hemophilia treatment centers or diagnostic hematology labs.

This description and any FAQs above were generated automatically from registry data and have not been verified by the manufacturer or by deviCERTS. Always check the official registry entry and the manufacturer's instructions for use before relying on them. Sources consulted: PDF NoFact VIII Immunodepleted Factor VIII Deficient Substrate Plasma C E ..., NoFact Immunodepleted Plasmas - r² Diagnostics, NOFACT VIII (K102851) — FDA 510(k) | Innolitics

Authorization Coverage (2 countries)

Regulatory Authorizations

European Union Active

IVDD

United States Active

FDA_510K

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (3)

  • FDA 510(k) K102851 24 fields · synced Sep 18, 2026
  • FDA UDI 39090041-f723-4e58-a3fe-7171eb0ca9df 35 fields · synced May 30, 2026
  • EUDAMED de872d61-94d3-4c95-9e76-54e902b697d5 61 fields · synced Jul 13, 2026